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Abstract 
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G protein-coupled estrogen receptor-1 
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(Directed by Professor Eun Jig Lee) 
 
 
 
Protocatechuic aldehyde (PCA), a phenolic aldehyde, has been 
proposed to have therapeutic potency for treatment of atherosclerosis. 
Although PCA is known to inhibit the migration and proliferation of 
vascular smooth muscle cells and intravascular thrombosis, the underlying 
mechanism remains unclear. In this study, I investigated the protective 
effect of PCA in endothelial cells and injured vessels in association with G 
protein-coupled estrogen receptor-1 (GPER-1) in vivo and in vitro. 
PCA treatment increased cAMP production in Human Umbilical 
vein endothelial cells (HUVECs) and GPER-1 expression was increased in 
both HUVECs and a rat aortic explant. PCA and G1, a GPER-1 agonist, 
reduced H2O2 stimulated ROS production in HUVECs, whereas G15, a 
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GPER-1 antagonist, increased ROS production further. This elevation of 
ROS production was inhibited by treatment of G15 with PCA or G1. TNFα 
stimulated the expression of inflammatory markers (VCAM-1, ICAM-1 and 
CD40), phospho-NF-κB, phospho-p38 and HIF-1α; however, treatment with 
PCA or G1 down-regulated this expression significantly. Accordingly, 
increased expression of inflammatory markers by treatment with G15 was 
inhibited by treatment with PCA.  
Treatment of rat aorta with PCA or G1 showed accelerated re-
endothelization of the endothelium and reduced sprouting and neointima 
formation. However, aortas from G15-treated rats showed decelerated re-
endothelization and increased sprouting and neointima formation. The 
effects of G15 were restored by treatment with PCA or G1. In addition, in 
the endothelia of these aortas, PCA and G1 increased CD31 and GPER-1 
and decreased VCAM-1 and CD40 expression. In contrast, the opposite 
effect was observed in G15-treated endothelium. These results suggest that 
GPER-1 might mediate the protective effect of PCA on the endothelium. 
 
 
 
 
 
 
 
Key words: protocatechuic aldehyde, human umbilical vein endothelial cells, 
endothelial dysfunction, atherosclerosis, g protein-coupled estrogen 
receptor-1
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I. Introduction 
 
Endothelial dysfunction is an imbalance between vaso-dilating and 
vaso-constricting substances produced by the endothelium leading to a 
proinflammatory state and prothrombic properties. Endothelial dysfunction 
is an important early event in the pathogenesis of atherosclerosis. 
Mechanisms that participate in endothelial dysfunction include reduced 
nitric oxide generation, oxidative excess, and upregulation of adhesion 
molecules.1,2 Previous studies on atherosclerosis have provided some 
information on this topic. For example, increased expression of proteins 
such as VCAM-1, ICAM-1, E-selectin, CD40, lectin-like oxidized LDL 
receptor-1 (LOX-1),3 production of matrix metalloproteinases (MMPs)4 and 
reactive oxygen species (ROS), and decreased secretion levels of NO5 
contribute to both initiation and progression of atherosclerosis. 
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To study about subject on the initiation and progression of 
atherosclerosis, it is quiet difficult to avoid mentioning about estrogen. It is 
well known that the estrogen is involved in sexual development and 
reproduction, but only recently, current researches show that it is also 
involved in many physiological processes including cardiovascular system. 
Results from the previous studies suggest that estrogen act to protect women 
before menopause against coronary heart disease,6 to decrease the risk of 
coronary heart disease on women after menopause,7 and to protect animals 
from atherosclerosis.8 From many studies involving the ones that I already 
have listed show us how estrogen could attenuate cardiovascular diseases by 
inhibition of immutable or intrinsic factors (age, sex and heredity) and 
modifiable or extrinsic factors (diet, obesity, tobacco consumption, stress 
and physical activity). Dyslipidemia, normally taking place at a condition 
where low-density lipoprotein (LDL) cholesterol becomes higher and high-
density lipoprotein (HDL) cholesterol falls, has both influences from 
immutable and modifiable factors. Interestingly, lipoprotein concentration 
among premenopausal women differs from men; total and LDL cholesterol 
are lower while HDL cholesterol is higher.9 However, post-menopausal 
women become to have higher LDL cholesterol than HDL in comparison to 
pre-menopausal women. This makes higher risk of dyslipidemia and 
atherosclerosis for post-menopausal women. However, there is little known 
about the relationship between estrogen and endothelial dysfunction and this 
study will be focused on this subject.  
As it was mentioned earlier, estrogen has protective effects against 
cardiovascular diseases, and its receptors ER α and ER β have been shown 
to mediate anti-atherogenic effects. Recently, a third membrane-bound ER 
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has emerged, G protein-coupled estrogen receptor-1 (GPER-1), that has 
beneficial effects on the cardiovascular system. GPER-1 is a seven 
transmembrane-domain G protein-coupled receptor (GPCR) that binds to 
17β-estradiol (E2) with high affinity and mediates estrogenic signals.10 
GPER-1 is widely expressed in human tissues, including the 
cardiovascular system.11,12 It was recently found that selective activation 
of GPER-1 potently inhibits the growth of human vascular smooth muscle 
cells.13 To find the role of GPER-1 on endothelial protection, G1 (GPER-1 
agonist) and G15 (GPER-1 antagonist) have been evaluated. These 
pharmacological agents are currently used most frequently as tools for 
investigating the role of GPER-1 in various systems.10 In this study, both 
agents were used to modulate GPER-1 in vitro and in vivo to investigate 
the protective role protocatechuic aldehyde (PCA) has in endothelial 
dysfunction through GPER-1. 
Protocatechuic aldehyde (PCA) is a phenolic aldehyde found in the 
aqueous extract of Salvia Miltiorrhiza that has recently been reported for its 
anti-oxidative effects. It was recently reported that PCA reduces myocardial 
infarct size and the activities of creatine kinase-MB and cardiac troponin in 
serum.14 Also, it can inhibit migration and proliferation of vascular smooth 
muscle cells and intravascular thrombosis.15 However, the underlying 
mechanism of PCA on reducing inflammation and its effects on endothelial 
dysfunction remains to be determined. In this study, we investigated the 
protective effect of PCA on endothelial cells and injured vessels in vivo in 
association with GPER-1. 
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II. Materials and Method 
 
1. Reagents, Antibodies and Assay kits 
 
Protocatechuic aldehyde (PCA) and GPER-1 agonist, G1  (Figure 1 
A) were purchased from Sigma Aldrich (St. Louise, MO, USA).  GPER-1 
antagonist, G15 was purchased from Calbiochem (San Diego, CA, USA). 
TNF-α and rat PDGF-BB were purchased from R&D Systems (Minneapolis, 
MN, USA).  
Antibodies for western blot analysis against GPER-1 (sc-134576), 
VCAM-1 (sc-8304), ICAM-1 (sc-7891), CD31 (sc-1506), CD40 (sc-975) 
were purchased from Santa Cruz (Delaware, CA, USA). phospho-MAPK 
(#9106S), NFκB (#4767), phospho-NFκB (#3033S), and HIF-1α (#3716S) 
were purchased from Cell Signaling Technology (Danvers, MA, USA).  
CM-H2DCFDA kit (#C6827) was bought from Invitrogen (Carlsbad, 
CA, USA) for ROS assay. Cultrex®  BME matrigel (3431-005-01) was 
bought from Trevigen (Gaithersburg, MD, USA) for sprout ring assay. MTS 
assay kit (G3580) was purchased from Promega (Madison, WI, USA). 
Cyclic AMP XP™ Assay kit (#4339) was brought from Cell signaling 
(Danvers, MA, USA). 
 
2. Ethics Statement 
 
All animals procedures were reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) of Yonsei 
University Health System (approval number: 2010-0268) and were 
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performed in strict accordance with the Association for Assessment and 
Accreditation of Laboratory Animal Care. 
 
3. Cell Culture 
 
Primary HUVECs were obtained from GIBCO (C-003-5C). 
HUVECs were cultured in EBM-2 (CC-3129) supplemented with serum kit 
(CC-4176) purchased from Lonza (Walkersville, MD, USA). Cells were 
maintained at 37°C humidified atmosphere of 5% CO2 incubator in 
collagen-coated dish supplied from Sigma Aldrich (C9791). The medium 
was changed every 2 days. For the experiments, HUVECs passage 3~8 were 
used 2 hours after serum depletion.  
 
4. Western Blotting 
 
Western blot analysis was performed using antibodies against 
GPER-1, VCAM-1, ICAM-1, CD31, CD40, phospho-MAPK, phospho-
NFκB, and HIF-1α. Cells were lysed in buffer containing 10 mM Tris, 400 
mM NaCl, 1 mM EDTA, and 0.1% (v/v) NP-40. Protein concentration of 
the cell was determined by the Bradford method.15 Equal amounts of the 
whole protein extract were subjected on 10% SDS PAGE followed by semi-
dry Western blotting. Subsequently, membranes were blocked with 5% BSA 
in TBST (50 mM Tris-HCl, pH 7.5 and 150 mM NaCl containing 0.05% 
(v/v) Tween 20). Blots were probed overnight with the dilutions of 
antibodies listed above in 5% (w/v) BSA containing TBST. After incubation 
with a secondary anti-rabbit antibody coupled to horseradish peroxidase, 
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immunocomplexes were visualized by enhanced chemi-luminescence 
purchased from Abfrontier (LF-QC0101, Seoul, Korea). 
 
5. Animal model – Common Carotid Balloon Injury 
 
Male Sprague Dawley rats (SD rats, ORIENT-Charles River 
Technology, Seoul, Korea) weighing 200~225 were housed in a 
temperature-controlled environment (24~26 °C) with a 12/12-hours reversed 
light and dark cycle, in a plastic cage with soft bedding, and given with a 
free access to tap water and standard laboratory chow.  
7 weeks old rats were randomly divided into seven groups and they 
were daily fed by intraperitoneal administration with the following amounts: 
Group 1 – Sham operated; Group 2 – Balloon injury; Group 3 – PCA 
(100mg/kg) with balloon injury; Group 4 – G1 (3.0 mg/kg) with balloon 
injury; Group 5 – G15 (3.0 mg/kg) with balloon injury; Group 6 – G15 (3.0 
mg/kg) and PCA (100mg/kg) with balloon injury; Group 7 – G15 (3.0 
mg/kg) and G1 (3.0 mg/kg) with balloon injury.  
For operative procedures, SD Rats were anesthetized with 5% 
isoflurane in a mixture of 70 % N2O and 30% O2 and it was maintained with 
2% isoflurane. Body temperatures were constantly checked with a rectal 
probe to maintain at 37.0 ± 0.2 °C using a homeothermic blanket control 
unit and a heating pad (Harvard Appratus, Holliston, MA, USA) during this 
procedures. After 2 weeks of intraperitoneal administration of substances, 
rats’ left common carotid arteries were isolated and a 2F Forgarty catheter 
(Edwards Lifesciences, Irvine, CA, USA) was introduced through the 
external carotid arteriotomy incision, advanced to the aortic arch, inflated to 
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produce moderate resistance, and gradually withdrawn 7 times as previously 
reported.16  
For Neointimal Formation experiment, animals were injected with 
each substance for 4 weeks more after 2 days of recovery and then sacrificed.  
For Re-endothelization assay, animals were injected with each 
substance for 1week more after 2 days of recovery and then injected with 
Evans Blue through tail vein. They were left injected for 30 minutes and 
then sacrificed to obtain the common carotid artery for evaluation. During 
these procedures, every effort was made to minimize animal usage and their 
sufferings.   
 
6. Measurement of ROS in HUVECs 
 
Levels of cellular reactive oxygen species were measured using the 
fluorescent probe 5-(and-6)-chloromethyl-2’, 7’-difluorodihydrofluorescein 
diacetate (CM-H2DFFDA). To prepare for the ROS assay, HUVECs 
cultured in EBM-2 supplemented with serum kit were changed into serum 
free media with 0.1% serum. Sample is treated for 24 hours and then, 1 hour 
of H2O2 100uM is added to each dish. After that, ROS assay procedures 
were followed as it was described from other studies.17 Samples were 
analyzed with FACS Calibur (BD Biosciences, Franklin Lakes, NJ, USA). 
 
7. cAMP assay in HUVECs 
 
cAMP assay kit was purchased from Cell Signaling (Cell Signaling, 
Danvers, MA, USA). HUVECs were seeded on 96 well plates in EBM-2 
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media with serum kit. After a day of incubation, serum media were replaced 
with serum free EBM-2 media with 0.1% FBS serum. After 2 hours of 
incubation, appropriate substances (Control, PDGF, PCA, G1, G15, 
G15+PCA, G15+G1) were added and incubated for 1 hr. Then steps were 
followed as it is stated on the manufacturer’s manual from Cell Signaling.  
 
8. Ex vivo Sprague Dawley Rat’s thoracic aorta culture 
 
Male Sprague Dawley Rats (100g) were housed in a controlled 
environment as previously described. After one week of stabilization, under 
anesthesia, rats were sacrificed and thoracic aortas were obtained. Thoracic 
aortas were chopped into several pieces and placed on Cell Culture Insert 
(PICM03050) purchased from Millicell®  (Billerica, MA, USA) in 6-well plate.  
Aortas were maintained in EBM-2 media with serum kit for one day 
to make them adapt to the experiment condition. Before the treatment of 
PCA, EBM-2 media with serum kit were removed and replaced with EBM-
2 serum free media. After 2 hours of serum depletion, PCA were added in 
time dependent manner. After the treatment, aortas were stored in 4% 
paraformaldehyde for fixation in 4 °C condition.  
 
 
9. Sprout Ring assay 
 
This method was used with some modifications by following 
previous work originally reported for mice aorta.18 Under anesthesia, 
thoracic aortas were removed from rat of 100 grams and transferred to a 50 
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ml conical tube containing ice-cold serum-free EBM-2 medium. The peri-
aortic fibro-adipose tissue was carefully removed with fine micro-dissecting 
forceps not to damage the aortic wall. Half a millimeter long aortic rings 
(approximately 25 per aorta) were sectioned. Ring-shaped explants of rat 
aorta were then embedded in BME Matrigel on Coverglass Bottom dish. 
EBM-2 serum media was added into the dish and left to be incubated for 3 
days. 3 days later, PCA, G1, G15, G15 and PCA, and G15 and G1 were 
added. The cultures were kept at 37°C in a humidified environment for a 
week and examined every day with an Olympus microscope at appropriate 
magnification. 
 
10. Vascular Histology and Immunohistochemical procedures 
 
Rat arteries were perfused with saline, removed, and fixed in 4% 
paraformaldehyde for 24 hours in 4°C. Then, they were embedded in 
paraffin and prepared in 4 μm cross sections. Rat aortas were stained with 
hematoxylin and eosin using standard protocol.19,20 For 
immunohistochemical analyses, sections were deparaffinized in xylene, 
rehydrated in graded ethanol solutions and washed with distilled water as 
described from other studies.21 Sections were blocked with 5% goat serum 
(005-000-121, Jackson ImmunoResearch, West Grove, PA, USA) in 
antibody diluent (S2022, Dako, Glostrup, Denmark) for 30 minutes and 
incubated overnight at 4°C with following antibodies: GPER-1, CD40, 
CD31 and VCAM-1 (1:150). After washing three times in TBS-T, slides 
were incubated for 1 hr with a biotinylated secondary antibody (Vector 
Laboratories, Burlingame, CA, USA). After rinsing three times in TBS-T, 
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RTU horseradish peroxidase streptavidin (SA5704, Vector Laboratories) 
was applied and the slides are incubated for 10 minutes. For color 
development, 3,3’-diaminobenzidine (DAB, D5637, Sigma) was used.  
 
11. MTS assay 
 
VSMCs grown on 100mm are trypsinized and seeded on 96 well 
plates. After 24 hours of incubation in DMEM serum media, serum media 
are replaced with serum free DMEM media. After 24 hours of serum 
depletion, appropriate drugs (Control, PDGF, PCA, G1, G15, G15 and PCA, 
G15 and G1) are added in serum free DMEM media to each group. For 
Control and PDGF group (10 ng/ml), no substances are added. After 24 
hours of drug treatment, media are removed and replaced with PDGF added 
drug-containing DMEM media except for Control group. After 24 hours 
later, steps are followed as it is stated on the manufacturer’s manual from 
Promega.  
 
12. Quantification of in vitro results, sprout length and neointima size 
of Rat arteries 
 
To perform image analysis, all images were taken under the same 
observation condition (light, contrast, magnification). Image analysis was 
performed by using Scion Image software and results were expressed as 
mean±SEM. Differences between groups for both in vivo and vitro results 
were evaluated using SPSS 18.0 software. Also graphs for Balloon injury, 
  13  
reendothelization assay and sprout ring assay were done by MedCalc 
software program. 
For morphologic analysis of neointimal formation, six round cross-
sections (4 μm thickness) were cut from the approximate middle of the 
artery. The intimal and medial cross-sectional areas of the carotid arteries 
were measured, and intima/media ratios were calculated. Antibody against 
GPER-1 was used for immunohistochemistry.  
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III. Results 
 
1. PCA increases GPER-1 expression in HUVECs and Sprague Dawley 
rat aortas 
 
To assess whether the effect of PCA on human umbilical vein 
endothelial cells (HUVECs) is mediated through GPER-1, cAMP levels and 
GPER-1 expression were measured after PCA treatment. PCA increased 
cAMP levels in a concentration-dependent manner. Significant elevation of 
cAMP levels was observed at 100 μM of PCA. Comparison of elevated 
cAMP levels between G1 (3.0 μM) and PCA stimulation showed that PCA 
was less potent than G1. GPER-1 expression was increased by PCA 
treatment in a concentration dependent manner with the highest expression 
after 6 hrs of incubation compared to that of the control (1.61 fold, P < 0.05) 
(Figure 1C, D). In the ex vivo culture of rat aortic explants, 100 μM of PCA 
increased GPER-1 expression after 6 hrs of treatment. (Figure 1E). Also the 
treatment of PCA in siGPER-1 had increased the expression level of GPER-
1 in RT-PCR (Figure 1F).  
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Figure 1. PCA induces expression of GPER-1. (A) The chemical structure 
of PCA and G1. (B) HUVECs were treated with G1 (3.0 μM) and PCA (10, 
50, or 100 μM) for 1 hr to measure the levels of cAMP activity. (C) 
HUVECs were treated with PCA (10, 50, or 100 μM) for 6 hrs. (D) 
HUVECs were treated with PCA (100 μM) over 1, 3, 6, 24 hrs. Blots are 
representative of 3 independent experiments. Densitometric analyses are 
presented as the relative ratio of GPER-1 to β-actin. Data are presented as 
mean±SEM; * P < 0.05. (E) Aortic segments were harvested from Sprague 
Dawley rats and cultured ex vivo in serum-free media with PCA (100 μM) 
over 1, 3, 6, 24 hrs. Segments were than fixed for immunohistochemistry of 
GPER-1 using 4% paraformaldehyde.  
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2. PCA decreases ROS production in HUVECs 
 
PCA reduced H2O2 stimulated ROS production in HUVECs in a 
concentration-dependent manner. Treatment with 50 or 100 μM of PCA 
significantly decreased ROS production (77.31±2.56%, P < 0.05 and 
57.18±8.33%, P < 0.01) stimulated by 100 μM H2O2 for 1 hr (Figure 2A). 
Comparison between G1 (3.0 μM) and PCA (100 μM) showed similar 
decreases in ROS production. Whereas, the GPER-1 antagonist G15 (3.0 
μM) increased ROS production further to 132.47±5.49% (P < 0.05). This 
elevation in ROS production was decreased to 78.33±7.73% (P < 0.05) and 
100.25±2.41% (P < 0.05) by treatment with PCA or G1, respectively 
(Figure 2B). 
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Figure 2. Protocatechuic aldehyde decreases ROS production. (A) 
HUVECs were pretreated for 24 hrs with various concentrations (10, 50, 
100 μM) of PCA. (B) HUVECs were pretreated for 24 hrs with PCA (100 
μM) and G1 (3.0 μM) and for 6 hrs with G15 (3.0 μM). Then, (A, B) 
HUVECs were treated with H2O2 (100 μM/ml) for 1 hr followed by 
measurement of ROS levels. (A, B) Both experiments are representative of 
3 independent experiments. Data are presented as mean±SEM; * P < 0.05, 
** P < 0.005, # indicates P < 0.05 compared to the control group. 
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3. PCA inhibits inflammatory signaling 
 
To evaluate whether PCA could down-regulate the inflammation in 
HUVECs caused by TNFα treatment, HUVECs were pre-treated with PCA 
(100 μM) or G1 (3.0 μM) for 24 hours.15 Then, 10 ng/ml TNFα was added 
for 6 hours to provoke inflammation. As shown in Figure 3A, TNFα 
stimulated the expression of VCAM-1, ICAM-1 and CD40; however, PCA 
down-regulated these expression levels significantly. G1 also down-
regulated their expression in a similar manner (Figure 3A). 
To investigate inhibition of the NF-κB signaling pathway by 
treatment with PCA or G1, endothelial cells were pre-treated with PCA (100 
μM) or G1 (3.0 μM) in the presence or absence of TNFα (10 ng/ml, 1 hr). 
As shown in Figure 3B, TNFα increased the expression of phospho-NF-κB, 
phospho-p38 and HIF-1α. This elevated expression was down-regulated 
significantly by PCA and G1 (Figure 3B). 
We also investigated whether G15, an antagonist of GPER-1, affects 
the expression of inflammatory markers in HUVECs and if PCA could act 
as a GPER-1 activator to block the activity of G15. As shown in Figure 3C, 
G15 showed GPER-1 inhibition activity by decreasing the expression level 
of GPER-1. Also, G15 increased VCAM-1, ICAM-1 and CD40 compared to 
the control. However, PCA treatment increased GPER-1 and inhibited 
inflammation markers dramatically. 
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Figure 3. Human umbilical vein endothelial cells (HUVECs) treated with 
tumor necrosis factor alpha (TNFα) and G15 induces inflammation. (A, B) 
HUVECs were pretreated with PCA (100 μM) and G1 (3.0 μM) for 24 hrs. 
(A) treatment with TNFα (10 ng/ml) for 6 hrs. (B) treatment with TNFα (10 
ng/ml) for 1 hr. (C) HUVECs were pre-treated with PCA (100 μM) for 24 
hrs and then treated with G15 (3.0 μM) for 6 hrs. Blots are representative of 
3 independent experiments. (A, B, C) Densitometric analyses are presented 
as the relative ratio of ICAM-1, VCAM-1, CD40, HIF-1α, GPER-1 or 
phospho-p38 to β-actin. (B) Densitometric analyses for phospho-NF-κB are 
presented as the relative ratio to NF-κB. Data are presented as mean±SEM; 
* P < 0.05, ** P < 0.005, *** P <0.001. 
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4. PCA inhibits angiogenesis 
 
To investigate the effect of PCA on angiogenesis, the Sprout Ring 
assay was performed. As shown in Figure 4A, treatment with PCA 
(3.74±1.89%, P < 0.001) or G1 (5.49±2.83%, P < 0.001) significantly 
prevented the length of sprouting compared to the serum only group 
(100.0%). Whereas, the addition of G15 (223.9165±32.96%, P < 0.01) 
dramatically increased the sprouting of VSMCs. Treatment with PCA or G1 
inhibited sprouting dramatically. 
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Figure 4. PCA inhibits angiogenesis. (A) Rat aortas were obtained from 
Sprague Dawley rats weighing 100 grams. Rat aorta segments placed on 
Matrigel were stimulated with FBS (10%) for 3 days. Then, the segments 
were treated with each substance for 48 hrs in media supplemented with 
FBS (10%). Sprout lengths were measured by using Scion Image software. 
(A, B) Values represent the means ± SEMs of 3 experiments. *** indicates 
P < 0.001 compared to the control group. ## and ### indicate P < 0.005 and 
P < 0.001, respectively, compared to the PDGF group. §§§ indicates P < 
0.001 compared to the G15 group. 
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5. Protocatechuic aldehyde accelerates re-endothelization in balloon-
injured arteries 
 
To investigate whether PCA also protects the endothelium through 
GPER-1 under in vivo conditions, endothelial recovery was evaluated after 
balloon denudation of the carotid artery in rats.22  
Sprague Dawley rats were pre-treated with the substances for 2 
weeks by intraperitoneal injection and then balloon injury of the common 
carotid artery was performed. Rats were injected with the substances for 
another 3 days after the surgical procedure. Before the isolation of carotid 
arteries, rats were injected with Evans Blue through the tail vein and left for 
30 min. As shown in Figure 5A, treatment with PCA or G1 accelerated re-
endothelization in balloon-injured arterial segments. The re-endothelized 
area in the PCA- and G1-treated rats was 69.35±3.81% (P < 0.001) and 
40.21±5.21% (P < 0.01), respectively, compared to the vehicle rats. The 
effect of PCA on re-endothelization was higher compared to that of G1. 
G15-treated rats did not show re-endothelization, similar to the vehicle 
treatment. Treatment of PCA on G15 treated aortas showed effective re-
endothelization (42.77±13.17%, P < 0.05), whereas treatment of G1 on G15 
treated aortas showed partial effects (6.90±1.52%, P < 0.05) (Figure 5A). 
As shown in Figure 5B, immunostaining for CD31, an endothelial 
marker, showed that the PCA- and G1-treated groups had a clear line of 
CD31 along the endothelium of the artery. Whereas, the vehicle- or G15-
treated groups showed no staining of CD31. This suggests that re-
endothelization occurred in PCA- or G1-treated arteries. GPER-1 expression 
was increased in PCA- and G1-treated endothelium compared to vehicle-
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treated arteries. Treatment with G15 decreased expression of GPER-1. 
Treatment with G15 and PCA or G1 did not suppress GPER-1 completely, 
but decreased expression of VCAM-1 and CD40 was observed. The 
expression of VCAM-1 and CD40 was increased by G15 treatment; 
however, treatment with PCA or G1 decreased their expression (Figure 5B) 
in the endothelium. 
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Figure 5. Protocatechuic aldehyde exhibits endothelial protection. (A) Re-
endothelization of a Sprague Dawley rat carotid artery determined by Evans 
Blue staining (de-endothelized areas are stained with blue). Ratios of 
surface covered by endothelium to the total area in sham, vehicle, and 
injured (Inj) groups treated with different substances as follows: PCA, G1, 
G15, G15 + PCA, G15 + G1 (n=4 each). (B) Cross sections of rat common 
carotid arteries stained with CD31 antibody 3 days after injury. Also, targets 
related to inflammatory markers were observed including VCAM-1, CD40 
and GPER-1. Data are presented as mean±SEM; *** indicates P < 0.001 
compared to the sham group. ## and ### indicate P < 0.005 and P < 0.001, 
respectively, compared to the vehicle group. § indicates P < 0.05 compared 
to the G15 + Inj. group. 
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6. PCA inhibits neointima formation in balloon-injured common 
carotid arteries (CCAs) 
 
We investigated the protective effect of PCA and G1 in a balloon 
injury model. Sprague Dawley rats (n=7) were treated for 2 weeks with the 
substances before the surgical procedure.23 After balloon injury of the CCA, 
rats were treated again with the substances for 4 weeks. After sacrifice, 
injured CCAs were isolated and paraffin embedded for H&E staining and 
immunohistochemistry for GPER-1.  
Figure 6A shows the representative images of each group treated 
with drugs along with bar graphs below. The results clearly show the 
effectiveness of PCA and G1 against neointima formation, whereas G15 
increased formation. PCA and G1 attenuated neointimal hyperplasia from 
14.00±0.95 inches2 to 9.65±0.76 inches2 (P < 0.001) and 8.418±0.73 inches2 
(P < 0.001), respectively. However, in G15-treated rats, neointima 
formation dramatically accelerated to 17.16 ±1.06 inches2 (P < 0.001). The 
effect of G15 was inhibited by treatment with PCA (6.06±0.39 inches2, P < 
0.001) or G1 (8.45±0.58 inches2, P < 0.001). 
Immunohistochemistry revealed that GPER-1 expression was 
increased in endothelia from rats treated with PCA or G1 compared to that 
of the vehicle-treated group. Arteries treated with G15 showed very low 
levels of GPER-1 expression. However, treatment with PCA or G1 restored 
GPER-1 expression in the endothelium (Figure 6B). 
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Figure 6. The effects of PCA, G1, G15, G15+PCA, and G15+G1 in CCA 
balloon-injured Sprague Dawley rats. (A, B) Seven-week-old Sprague 
Dawley rats (200 g) were treated with each substance by intraperitoneal 
injection for 2 weeks and then common carotid arteries from the rats were 
balloon injured. Substances were injected for another 4 weeks and then 
sacrificed for (A) H & E staining of common carotid arteries. Graph shows 
the percentage of neointima areas of Sprague Dawley rats from each group 
(n=7). Measurements were made using Scion Image software. (B) 
immunohistochemistry of rat aortas shows GPER-1 expression in the linings 
of the aorta from the same tissues used for Figure 5A. Data are presented as 
mean±SEM; *** indicates P < 0.001 compared to the sham group. ### 
indicates P < 0.001 compared to the vehicle group. §§§ indicates P < 0.001 
compared to the G15 + Inj. group. 
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7. The mode of action of PCA and GPER-1 antagonist 
 
To further verify the relationship between PCA and GPER-1 and 
G15’s intervention in this relationship, we have treated G15 to HUVECs to 
see whether G15 can inhibit the cAMP activity of GPER-1. In Figure 7A 
shows that G15 has a mild inhibitory effect on cAMP activity. Also, the 
treatment of G15 with PCA or G1 has decreased activity level mildly 
compared to PCA or G1 only treated group. This shows that G15, which is 
unknown for its capability on GPER-1 mechanism, does a slight inhibition 
on cAMP activity of GPER-1 in HUVECs.  Also similar patterns were 
observed in Supplementary Figure 7B as it mildly inhibits p-AMPK, which 
is a well-known downstream protein of cAMP, increased by PCA and G1. 
These data suggest G15’s inhibitory effect depend less on cAMP inhibition 
to cause inflammatory and oxidative effects. We believe that there are non-
cAMP pathways that G15 can act on during GPER-1 activation. Further 
researches are needed to verify the G15’s action on GPER-1 as an 
antagonist of GPER-1.  
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Figure 7. PCA and G15 effects on GPER-1 related mechanism. (A) HUVECs in 
96 well were treated with adequate substances (PCA, G1, G15, G15+PCA, 
G15+G1) for 1 hr after 2 hrs of serum depletion. Graphs are representative of 3 
independent experiments. * indicates P < 0.05 compared to the control and G15 
treated group. (B) HUVECs were pretreated with adequate substances for 24hrs 
(PCA, 100 μM; G1, 3.0 μM). Then G15 (3.0 μM) were added for 6 hrs for p-
AMPK and AMPK. Blots are representative of 3 independent experiments. * 
indicates P < 0.05 compared to the control group. # indicates P < 0.05 compared to 
the G15 group.  
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IV. Discussion 
 
PCA has exhibited various therapeutic effects in different cell types 
such as vascular smooth muscle cells, cancer cells, and a cardiac animal 
model.15,24,25 However, PCA has not been evaluated for its effect against 
endothelial dysfunction and has rarely been studied in HUVECs. Unlike 
PCA, GPER-1 has been consistently reported for its role in attenuating 
atherosclerosis because it regulates the activity of many vasoconstrictors 
and proliferation of vascular smooth muscle cells.10 Thus, it is becoming 
increasingly difficult to ignore the importance of endothelial cells and 
GPER-1 in developing therapeutic agents against endothelial dysfunction 
and atherosclerosis. 
The activation of GPER-1 by PCA protects endothelial cells in 
various ways from inflammation in vitro. One of them is the inhibition of 
ROS production, which is closely related to NF-κB. The reduction of ROS 
by PCA and GPER-1 agonist has shed light on the relationship between 
GPER-1 and NF-κB. Previous studies have pointed out the beneficial effects 
of GPER-1 on atherosclerosis, but they have failed to find connections with 
NF-κB.26 However, we found that G1 and PCA could down-regulate the 
secondary molecules involved in NF-κB signaling. Such cytokine-mediated 
upregulation of NF-κB was shown to implicate HIF-1α,27 CD40 and other 
adhesion molecules (E-selectin, VCAM-1 and ICAM-1),28,29 which were 
effectively inhibited by PCA and GPER-1 agonist. We also showed that 
PCA and G1 down-regulated the phosphorylation of p38-mitogen activated 
protein kinase, which also has been recently reported from a previous study 
using ApoE-/- mice.30 Although other possible mechanisms have yet to be 
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ruled out, our results strongly suggest a model in which PCA increases 
GPER-1 to down-regulate inflammatory molecules. 
The activation of GPER-1 as a type of GPCR can result in beneficial 
effects against inflammation. Cyclic-AMP and Ca2+ are most frequently 
associated with GPER-1 signaling. GPER-1 couples to Gαs resulting in 
cAMP production and Gαi/o to partly yield cAMP.10 PCA and G1 have been 
shown to increase the production of cAMP, but it remains if the GPCR α 
subunit of PCA can or cannot be activated. The activation of GPCR 
automatically activates regulatory molecules, including GRKs31 and β-
arrestin32. These molecules determine the role of GPER-1 once they are 
desensitized. It still remains unclear whether PCA or G1 can alter the 
expression of these molecules to change the fate of GPER-1. 
PCA and G1 had inhibitory effects against angiogenesis in the 
Sprout Ring assay. In contrast, G15 treatment showed that it accelerated 
angiogenesis to a much greater extent than the serum only group. From the 
MTS assay (Supplementary data), PDGF increased VSMC proliferation, 
which was decreased by PCA and G1. Treatment with G15 increased  
proliferation, but this angiogenic effect of G15 was inhibited by treatment 
with PCA or G1. These results expand the effects of PCA as an anti-
angiogenic agent and show that PCA could interact with proteins other than 
GPER-1 since most GPCRs and their kinases are known to accelerate 
angiogenesis.33  
G15, an antagonist of GPER-1, has been recently discovered and its 
effects have not been evaluated in endothelial cells. Its involvement in 
blocking estradiol 17β-D-glucuronide-induced cAMP production34 and 
upregulation of the angiotensin AT1 receptor have been reported.35 Our in 
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vitro results, showed that G15 acts as a pro-inflammatory agent to increase 
the expression of inflammatory markers such as VCAM-1, ICAM-1 and 
CD40. Also, the pro-inflammatory characteristics of G15 were observed for 
angiogenesis, neointimal formation and attenuation of re-endothelization. 
To verify whether PCA can act against the effects of G15, HUVECs were 
pre-treated with PCA before treatment with G15. The results showed that 
PCA effectively inhibited the pro-inflammatory effects of G15. Consistent 
with these results, the CCA of balloon-injured rats showed that PCA 
inhibited the pro-inflammatory effects of G15 by reducing neointimal 
hyperplasia. In accordance with the balloon injury results, the endothelia of 
rat aortas co-treated with PCA and G15 showed noticeable recovery from 
balloon injury. 
To reveal the correlation between HUVECs and aortas, we 
performed immunohistochemistry for GPER-1, CD40, CD31 and VCAM-1. 
We have observed that rats co-treated with PCA and G1 had definite 
expression of CD31 and GPER-1, suggesting that GPER-1 affects 
endothelial cell survival. Also, the immunohistochemistry results for CD40 
and VCAM-1 showed that PCA and G1 effectively inhibited both these 
molecules, similar to observations from the HUVEC experiment. In contrast, 
aortas from G15-treated rats did not show expression of either GPER-1 or 
CD31. Surprisingly, immunohistochemistry for VCAM-1 and CD40 was 
clearly observed in the vehicle and G15-treated groups. Furthermore, 
treatment with G15 and PCA or G1 in rats showed recovery of CD31 and 
GPER-1, indicating that PCA and G1 act through GPER-1 in a similar 
manner. 
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To further explain the various roles of PCA in the endothelium, 
studies on the structure of PCA are required. O’Brien et al36 showed that 
aldehyde has therapeutic effects against some human diseases. Therefore, 
we have compared two different protocatechuic substances, aldehyde and its 
acid form (data not shown), in order to reveal the structural function of this 
particular molecule. We showed that protocatechuic acid does not have the 
same therapeutic effects as the aldehyde form. This provided us with 
information on the structural importance of this molecule with respect to 
endothelial dysfunction. Further research will be required to elucidate the 
structural function of PCA for the development of new drugs against 
atherosclerosis. 
GPER-1 and ring-structured aldehyde may be closely associated 
with each other. A recent study by Hamza et al37 showed that 
hydroxyproline, which is one of the ring-structured aldehydes, activates 
GPER-1 through a different mechanism from estrogen. They also suggested 
that it stabilizes the active site of GPER-1 by forming a network of 
hydrogen bonds between the residues of GPER-1. PCA and 3,4-
dihydroxybenzaldehyde share many structural features with hydroxyproline 
that need to be evaluated to confirm whether PCA acts in a similar manner 
as hydroxyproline. However, in the present study, we compared data on 
PCA and G1 and showed that PCA exhibited similar therapeutic effects as 
G1, thus demonstrating the likelihood that PCA can act like hydroxyproline. 
Currently, it is difficult task to find the exact mode of activation by 
PCA. So, by comparing the effects of G1 and PCA in the presence of G15, 
it would clarify the function of PCA whether it can act like G1 or GPER-1 
agonist in activating cAMP. The results from Supplementary Figure 2A 
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show that the treatment of PCA or G1 in the presence of G15 decreased 
cAMP in similar degree in comparison to the HUVECs treated with PCA or 
G1 without G15. This shows that PCA and G1 share the similar mechanism 
in interacting with GPER-1 for cAMP activation and that their activity 
cannot be fully inhibited by the treatment G15. This implicates that PCA 
can interact with GPER-1 like G1 agonist. Further researches are needed to 
find whether PCA and GPER-1 bind directly or not. To further verify the 
relationship between PCA and GPER-1 and G15’s intervention in this 
relationship, we have treated G15 to HUVECs to see whether G15 can 
inhibit the cAMP activity of GPER-1. In Supplementary Figure 2A shows 
that G15 has a mild inhibitory effect on cAMP activity. Also, the treatment 
of G15 with PCA or G1 has decreased activity level compared to PCA or 
G1 only treated group. This shows that G15, which is unknown for its 
capability on GPER-1 mechanism, does a slight inhibition on cAMP 
activity of GPER-1 in HUVECs.  Also similar patterns were observed in 
Supplementary Figure 2B as it mildly inhibits p-AMPK, which is well-
known downstream protein of cAMP, increased by PCA and G1. This data 
suggests G15’s inhibitory effect depend less on cAMP inhibition to cause 
inflammatory and oxidative effects. We believe that there are non-cAMP 
pathways that G15 can act on during GPER-1 activation. Further researches 
are needed to verify the G15’s action on GPER-1 as an antagonist of 
GPER-1. 
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V. Conclusion 
 
In summary, the present study provides the first evidence that PCA 
attenuates endothelial dysfunction and atherosclerosis in vitro and in vivo 
through activation of GPER-1. These findings indicate that PCA is an 
important candidate compound for the treatment of atherosclerosis. 
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Abstract (in Korean) 
 
Protocatechuic Aldehyde 의동맥경화증 억제 기전 및 
G protein-coupled Estrogen Receptor-1과의 연관성 
 
<지도교수 이은직> 
 
연세대학교 대학원 의과학과 
 
공병수 
 
 
Protocatechuic aldehyde (PCA)는 훼놀성 알데히드(phenolic 
aldehyde)로써 동맥경화증에 대한 치료효과가 있다. 비록 PCA가  혈관 
평활근 세포(vascular smooth muscle cells)의 증식, 이동 및 혈관 내 
혈전생성(intravascular thrombosis)를 억제한다고 알려져 있지만, 아직 
근본적인 기전은 규명 되지 않았다. 이 논문에서는, 내피세포와 in vivo 
동맥경화 모델에서의 PCA의 혈관 보호 효과와 그것에서의 G protein-
coupled estrogen receptor-1 (GPER-1) 과의 관계를 확인해보려 한다.  
사람 혈관 내피세포 (Human Umbilical Vein Endothelial 
cells, HUVECs)와 쥐 대동맥 외식편 (Rat aortic explant)에서 PCA 
처리 시 cAMP 생성과 GPER-1 발현이 유의미성 있게 증가되는 것을 
확인할 수 있었다. PCA 와 GPER-1 작용제 (agonist)인 G1 은 
과산화수소(H2O2) 에 의해 증가된 활성산소(Reactive oxygen 
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species, ROS) 생성을 감소시키지만 G15 길항제(antagonist)의 
경우에는 반대로 증가시켰다. 또한,  G15 에 의한 ROS 증가는 
PCA 와 G1 을 함께 처리하였을 때 억제되었다. 비슷한 맹락에서 
TNFα 에 의해 증가된 염증 표지자들 (VCAM-1, ICAM-1, CD40, 
phospho-NF-κB, phospho-p38 and HIF-1α) 도 PCA 와 G1 에 의해서 
의미있게 감소하였다. G15 는 TNFα 처럼 염증 표지자들을 
증가시키지만 PCA 에 의해서 이것 또한 억제되었다. 
내피세포재현성(Re-endothelization), 대동맥 고리 성장(aortic ring 
sprouting)과 위 내막 형성(neointima formation) assay 에서 Sprague 
Dawley(SD) 쥐 대동맥을 PCA 혹은 G1 으로 처리하였을 때, 증가된 
내피세포재현성, 감소된 대동맥 고리성장과 감소된 위 내막 형성을 
확인하였다. 반대로, G15 를 처리한 동물에서는 감소된 
내피세포재현성, 증가된 대동맥 고리성장과 위 내막 형성을 확인할 수 
있었다. G15 에 의해서 촉진된 효과는 PCA 나 G1 처리에 의해서 
억제되었다. 또한 이러한 대동맥의 내피에서 면역조직화학 
(Immunohistochemistry, IHC) 염색을 진행하였을때, CD31 과 
GPER-1 의 증가와 VCAM-1 과 CD40 발현의 억제를 확인할 수 
있었다. 반면 G15 의 IHC 결과에서는 반대 양상을 보였다. 이러한 
결과를 비추어보았을 때, PCA 는 내피세포에서 동맥경화 억제 효과를 
나타내며 이 효과들은 GPER-1 을 통해 조절될 것이라고 생각된다. 
 
핵심되는 말: protocatechuic aldehyde, 사람 혈관 내피세포, 내피세포 
기능부전, 동맥경화, g protein-coupled estrogen receptor-1 
